Australia's most trusted
source of pharma news
Friday, 09 May 2025
Posted 6 May 2025 PM
UCB has seen a quick turnaround for its latest seizure treatment Fintepla which was added to the PBS roughly five months after TGA approval.
Fintepla is the first dual-action anti-seizure medication (ASM) that targets both the serotonin and sigma-1 pathways and was recommended at the PBAC’s November 2024 meeting ahead of the TGA’s approval later that month.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.